New combo therapy targets tough leukemia
NCT ID NCT07454226
First seen Mar 17, 2026 · Last updated Apr 25, 2026 · Updated 3 times
Summary
This study tests whether adding two targeted drugs (olverembatinib or gecacitinib) to standard chemotherapy and venetoclax can improve outcomes for adults with a high-risk leukemia called Ph-like ALL. About 30 participants will receive treatment based on their specific genetic changes. The main goal is to see if the cancer becomes undetectable after three months of therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.